Analysts/Institutional Investor Meet/Con. Call Updates

AI summary - Q2FY27 consolidated revenue grew 11% y-y to INR821 Cr; EBITDA rose 41% to INR202 Cr with 25% margin - H1FY27 consolidated revenue grew 21% y-y to INR1,489 Cr; EBITDA margin improved to 25.5% - Completed Bliss GVS Pharma acquisition, expanding pharma formulation capabilities and global reach - Signed 6-year supply deal with US specialty metal manufacturer; initial revenue INR100-150 Cr this year - Order book at INR17,496 Cr, providing multi-year revenue visibility - Bliss EBITDA margin steady state guided at 22-24%; synergy benefits expected in 3-4 quarters - Focus on integrating acquisitions, expanding pharma and performance materials, and improving working capital - Standalone EBITDA margin strong at 34%, but guidance maintained at 24-26% - Target consolidated H2FY27 revenue INR2,400-2,500 Cr; annualized run rate INR4,800-5,000 Cr - Jayhawk margin improvement via process optimization, sourcing, and effluent cost reduction